|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Risk factors related to the appearance of hyperkalaemia in the CKD group were glomerular filtration rate (GFR) (P<.001), plasma creatinine (P<.001), plasma sodium (P<.001), haemoglobin (P=.028), diastolic blood pressure (P=.012), intake of ACE inhibitors and/or angiotensin ii receptor blockers (P=.008), treatment with metformin (P<.001) and diabetes (P=.045).
|
30898450 |
2020 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In CKD, concomitant use of iron preparations (OR = 0.3, 95% CI: 0.2-0.7; P-value = 0.002) and of high dosage of angiotensin-converting enzyme inhibitors/angiotensin II-receptor blockers (OR = 0.5, 95% CI: 0.3-0.9; P-value = 0.022) were protective factors against ESA hyporesponsiveness.
|
31521117 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure.
|
31498767 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increased protein-bound uremic toxin, parathyroid hormone, glucocorticoid, and angiotensin II levels that are observed in CKD all have a negative effect on muscle mass and endurance.
|
31474705 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Using Cox regression analysis, hazard ratios (HRs) were estimated after adjusting for the following covariates: age, sex, diabetes mellitus, diabetic nephropathy, cardiovascular disease, anemia, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists, loop diuretics, cigarette smoking, body mass index, serum albumin, systolic blood pressure, urine albumin-to-creatinine ratio, and CKD stage.
|
30168046 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease.
|
30786856 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
|
31010001 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.
|
30992195 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To estimate the effects of RAS-I in this population, we performed a systematic review and meta-analysis of randomized controlled trials where treatment with angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers were compared with placebo or active controls in adults with non-diabetic CKD.
|
30948820 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Optimal management of CKD includes cardiovascular risk reduction (eg, statins and blood pressure management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs), and adjustments to drug dosing (eg, many antibiotics and oral hypoglycemic agents).
|
31573641 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been recently shown that impaired nighttime melatonin secretion is associated with nighttime urinary angiotensinogen excretion, a surrogate marker of intrarenal RAS activation and renal damage in patients with CKD.
|
30610209 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
ACE2 and NEP generate renoprotective angiotensin (1-7) from angiotensin II and angiotensin I, respectively, and therefore could have a major role in chronic kidney disease (CKD).
|
29561187 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results highlight the importance of AngII as a driver of resistance vessel structural, functional, and biomechanical dysfunction and provide insight as to how AT1 receptor blockade exerts therapeutic efficacy in CKD.
|
29425281 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Adiponectin attenuates kidney injury and fibrosis in deoxycorticosterone acetate-salt and angiotensin II-induced CKD mice.
|
29873514 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The classical treatments with angiotensin II receptor blocker (ARB) or the angiotensin-converting enzyme inhibitor (ACE I) have shown a clinical effect in CKD.
|
30403908 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Short-term CKD rats were administered with AngII receptor blocker (ARB).
|
29889834 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Measures that counter acid retention, such as providing alkali or modifying the quantity or type of dietary protein, reduce the levels of endothelin, angiotensin II, aldosterone, and ammoniagenesis, slowing progression of CKD.
|
29140821 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In hypertensive patients without CKD, ingestion of ≥1 BP-lowering medications at bedtime, mainly those modulating or blocking the effects of angiotensin II, compared with ingestion of all such medications upon-awakening, resulted in improved ambulatory BP control (significant further decrease of asleep BP and enhanced sleep-time relative BP decline) and reduced risk of incident CKD.
|
29531290 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Losartan, an angiotensin II receptor blocker, has been widely used as the first choice of treatment in chronic renal diseases.
|
28146117 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease.
|
28873219 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show that ER stress inhibition through 4-phenylbutyric acid (4-PBA) administration decreases blood pressure, albuminuria, and tubular casts in an angiotensin II/deoxycorticosterone acetate/salt murine model of CKD.
|
28148966 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The statement, that AGT may be a good biomarker of CKD after acute kidney injury due to HUS requires prospective studies with follow-up from the acute phase of the disease on a larger group of patients.
|
27982687 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Evaluation of gene-gene and gene-environment interactions using epistasis analysis revealed an interaction between AGT M235T and angiotensin II receptor type 1 A1166C in CKD (OR: 0.767; 95% CI: 0.609-0.965).
|
29296205 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II) is a risk factor for the initiation and progression of chronic kidney disease (CKD), as elevated Ang II levels can lead to podocyte injury.
|
28878222 |
2017 |